Tag Archives: gild

Bristol-Myers Looks Beyond Cancer To Build Portfolio

For the past year, the talk concerning Bristol-Myers Squibb has focused on its cancer drugs. This is understandable, since Bristol-Myers’ (BMY) recently launched Opdivo is projected to take in nearly $9 billion a year by 2020, and looks like it will carry other immuno-oncology drugs such as Yervoy to greater sales as well. At the same time, Bristol-Myers has scaled back its ambitions in virology as Gilead Sciences (GILD) has taken the lead in the

Gilead Seen Staying Top Dog In HCV, But Merck Rising

On Wednesday, the morning after the annual Liver Meeting wrapped up in San Francisco, Wall Street analysts sifted through the implications of the data rolled out there for the vast hepatitis C market. Analysts saw continued dominance for Gilead Sciences (GILD) in genotype 1 of the hepatitis C virus (HCV), which accounts for the majority of cases. Gilead’s Harvoni, a combination of sofosbuvir (sold separately as Sovaldi) and ledipasvir, is already

Gilead, Regeneron Stocks Weather Drug Pricing Furor

Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry’s drug-pricing practices and fears of greater regulation. But two biotechs with top fundamentals — Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN), the focus of the Screen of the Day — have maintained strong ratings and held up in